Key statistics dashboard for Eledon Pharmaceuticals, Inc. (ELDN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells.
Stock Data
| Price | $2.67 |
| Market Cap | $206M |
| Beta | 0.84 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -2.70 |
| Price / Book | 4.21 |
| P/S | 0.00 |
| P/FCF | -2.79 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 7.90 |
| Quick Ratio | 7.90 |
| Cash Ratio | 0.58 |
| Debt / Equity | 0.01 |
| Debt / Assets | 0.37% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.63 |
| Cash per share | 0.78 |
| FCF per share | -0.65 |
| Tangible Book Value per share | 0.35 |
| Dividend per share | 0.00 |
Related companies: ABEO · ACHV · ALLO · AVIR · EDIT · HUMA · PBYI
Explore sector: Healthcare · Biotechnology
More sections of ELDN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks